FAQ on Aditxt Inc.'s ADI-100 Autoimmune Therapy Advancements and Mayo Clinic Study

What is ADI-100 and what does it target?

ADI-100 is the lead autoimmune therapy candidate developed by Aditxt’s subsidiary Adimune Inc., designed to induce immune tolerance to glutamic acid decarboxylase (GAD), a key trigger in several autoimmune conditions including type 1 diabetes and stiff person syndrome.

What were the findings of the Mayo Clinic-led study on ADI-100?

The study validated preclinical findings, confirming ADI-100’s ability to promote antigen-specific suppression through tolerogenic dendritic cells without enhancing harmful immune activity, indicating its potential as a safe and effective treatment for autoimmune diseases.

What are the next steps for ADI-100 following the study?

With GMP manufacturing completed and stability testing underway, Aditxt plans to file regulatory submissions in the U.S. and Germany in the second half of 2025 to support upcoming clinical trials for ADI-100.

How does Aditxt Inc. operate in the health innovation sector?

Aditxt operates as an innovation platform focusing on immune health and precision health, with plans to introduce programs in public health and women’s health, collaborating with research institutions and industry partners to advance health solutions.

Who are Aditxt’s partners in advancing its health programs?

Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. for infectious diseases and a merger agreement with Evofem, aiming to expand its health innovation programs, subject to certain conditions and approvals.

Where can I find more information about Aditxt Inc. and its developments?

For more information, visit Aditxt’s website at www.Aditxt.com or check the latest news and updates relating to ADTX in the company’s newsroom at https://ibn.fm/ADTX.

Why is the advancement of ADI-100 significant?

The advancement of ADI-100 is significant because it offers a potential new treatment for autoimmune conditions by inducing immune tolerance to GAD, addressing a key trigger in diseases like type 1 diabetes, with promising safety and efficacy profiles from preclinical studies.

When are the regulatory filings for ADI-100 expected?

Regulatory filings for ADI-100 in the U.S. and Germany are planned for the second half of 2025, following the completion of GMP manufacturing and stability testing, to support the initiation of clinical trials.